Lori J. Pierce
Lori Pierce is a breast radiation oncologist and ASCO past president focused on equity in cancer care.
Radiation oncologist studying radiotherapy in BRCA carriers and breast cancer outcomes by race. Served as ASCO president in 2020-2021 and is a senior NRG Oncology investigator.
| Title | Journal | Year |
|---|---|---|
| Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy | Breast Cancer Research and Treatment | 2010 |
| Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer | Journal of Clinical Oncology | 2006 |
Pages like this
not linked directly; found by shared links- PersonMax S. Wicha
Shares University of Michigan Rogel Cancer Center, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- InstitutionUniversity of Malaya Medical Centre
Shares BRCA1 / BRCA2 (HRD), IMRT / IGRT (modern external beam), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonLeif W. Ellisen
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- InstitutionLagos University Teaching Hospital
Shares BRCA1 / BRCA2 (HRD), IMRT / IGRT (modern external beam), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonTheodore S. Lawrence
Shares University of Michigan Rogel Cancer Center, IMRT / IGRT (modern external beam).
- PairingGermline BRCA test → adjuvant PARP inhibitor
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonClifford A. Hudis
Shares American Society of Clinical Oncology (ASCO), HR-positive / HER2-negative breast cancer.
- PersonJennifer K. Litton
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.